Technology ID
TAB-2428
Broadly Neutralizing Human Anti-HIV Monoclonal Antibody 10E8 and Related Antibodies Capable of Neutralizing Most HIV-1 Strains
E-Numbers
E-253-2011-0
E-253-2011-1
E-253-2011-2
E-253-2011-3
Lead Inventor
Connors, Mark
Lead IC
NIAID
Co-Inventors
Mascola, John
Laub, Leo
Huang, Jinghe
Kwong, Peter
Ofek, Gilad
Zhu, Jiang
Nabel, Gary
Georgiev, Ivelin
Yang, Yongping
Rudicell, Rebecca
ICs
NIAID
Applications
Vaccines
Therapeutics
Therapeutic Areas
Infectious Disease
Immunology
Development Stages
Pre-Clinical (in vitro)
Development Status
- In vitro data available
- In vivo data available (animal)
Research Products
Antibodies
The uses for human anti-HIV monoclonal antibody 10E8 and its variants include passive immunization, therapeutic vaccination, and the development of vaccine immunogens. 10E8 is one of the most potent HIV-neutralizing antibodies isolated and it neutralizes up to 98% of diverse HIV-1 strains. 10E8 is specific to the membrane-proximal external region (MPER) of the HIV envelope protein gp41 and 10E8 is orthogonal to other anti-HIV antibodies. In combination with other antibodies 10E8 may provide an antibody response that neutralizes nearly all strains of HIV-1. Additionally, 10E8 effectively induces antibody-dependent cellular cytotoxicity (ADCC) indicating its potential use for therapeutic vaccine strategies. Further, 10E8 is a tool for immunogen design and validation of immunogen structure.
NIAID is currently developing certain embodiments of 10E8 for clinical use. Therefore, for some fields of use, NIH will evaluate a license applicant's capabilities and experience in advancing similar technologies through the regulatory process. This technology is not eligible for the NIH's start-up license program.
NIAID is currently developing certain embodiments of 10E8 for clinical use. Therefore, for some fields of use, NIH will evaluate a license applicant's capabilities and experience in advancing similar technologies through the regulatory process. This technology is not eligible for the NIH's start-up license program.
Commercial Applications
- Passive protection to prevent HIV infection
- Passive protection to prevent mother-to-infant HIV transmission
- Topical microbicide to prevent HIV infection
- Gene-based vectors for anti-gp41 antibody expression
- Therapeutic for the elimination of HIV infected cells that are actively producing virus
Competitive Advantages
- One of the most potent Human broadly-neutralizing anti HIV antibodies isolated to date
- Broad reactivity and high affinity to most HIV-1 strains
- Activity is highly complementary to existing broadly neutralizing antibodies, such as CD4 binding site antibodies
- Not auto-reactive
Licensing Contact: